Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatches track hidden heart risk in blood cancer patients

NCT ID NCT07711327

Knowledge-focused Sponsor: Tina Baykaner Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study investigates how often atrial fibrillation (AF), a type of irregular heartbeat, occurs in people with certain blood cancers who are starting a targeted cancer drug called a Bruton's tyrosine kinase inhibitor (BTKI). Researchers will follow 500 participants—400 starting BTKI therapy and 100 with similar cancers not on BTKIs—using smartwatches and heart monitor patches to detect AF and other rhythm problems over 12 months. The goal is to understand whether BTKI therapy raises the risk of AF and how that might affect cancer treatment and overall health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bruton's tyrosine kinase inhibitor (BTKI) therapy
What this could lead to
If this study finds a clear link, it could help doctors monitor and manage heart rhythm problems in blood cancer patients on BTKI therapy.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not apply to all patients or cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with a diagnosis of chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma who are being newly started on BTKI or non-BTKI therapy at Stanford University, City of Hope, or UCSD oncology clinics.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age greater than 18 years * Diagnosis of chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) * New initiation of Bruton's tyrosine kinase inhibitor (BTKI) therapy or non-BTKI therapy (eg, venetoclax based) for management of hematologic malignancy Exclusion Criteria: * Prior exposure to BTKI therapy * History of persistent atrial fibrillation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Arrhythmias, Cardiac atrial fibrillation B-cell chronic lymphocytic leukemia hematopoietic and lymphoid system neoplasm Lymphoma, B-Cell, Marginal Zone mantle cell lymphoma marginal zone lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Chronic lymphocytic leukemia Mantle cell lymphoma Marginal zone lymphoma Waldenstrom macroglobulinemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Stanford Health Care

    Stanford, California, 94305, United States

  • UC San Diego Health

    San Diego, California, 92103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.